| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_35c78f5fa92922b5b31c960bd7d015a9
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_70c2849f97beaa9c21404222ee8222ce
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_59e1d955a7b1560dc68cf7fd800e8fac |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2300-00 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2815
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2866
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-7068
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-39558
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-3955 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-7068
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-28 |
| filingDate |
2011-05-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2017-01-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_724aea475e55641a510cbf4f6d1544f7 |
| publicationDate |
2017-01-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-9539322-B2 |
| titleOfInvention |
Method of enhancing an antitumor T cell response by administering an anti-IL-6 receptor antibody |
| abstract |
An objective of the present invention is to provide novel therapeutic agents for cancer, which have an excellent antitumor effect in cancer patients by enhancing their immune function. The present inventors discovered that the administration of at IL-6 inhibitor and/or gemcitabine or a salt thereof to tumor-bearing organisms yields an excellent antitumor T cell response-enhancing effect, and completed the present invention. In addition, the present inventors discovered that the T cell response-enhancing effect produces an excellent antitumor effect. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10744201-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11377678-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10874677-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9750752-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11667720-B1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11136610-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11021728-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11692037-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10231981-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10697883-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11622969-B2 |
| priorityDate |
2010-05-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |